(Q34516047)

English

In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Marcia S Osburne

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David M Rothstein

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ronnie Farquhar

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Christopher K Murphy

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

1 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The Journal of Antibiotics

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

80-85

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

21 January 2018

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

21 January 2018

Method of reliable determination of minimal lethal antibiotic concentrations

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

21 January 2018

Development potential of rifalazil

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

7 January 2021

based on heuristic

inferred from DOI database lookup

Killing effects of antibiotics and two-fold antimicrobial combinations on proliferating and non growing staphylococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

7 January 2021

based on heuristic

inferred from DOI database lookup

The mutant selection window and antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.11

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/JA.2006.11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34516047&oldid=2196730525"